- 著者
- Ryuichiro TANAKA Hiroo TAKAYAMA Masami MOROTOMI Toshikata KUROSHIMA Sadao UEYAMA Keisuke MATSUMOTO Akio KURODA Masahiko MUTAI
- 出版者
- Japan Bifidus Foundation
- 雑誌
- Bifidobacteria and Microflora (ISSN:02869306)
- 巻号頁・発行日
- vol.2, no.1, pp.17-24, 1983 (Released:2011-02-23)
- 参考文献数
- 25
- 被引用文献数
- 130 184
We studied the effects of administration of TOS, a new growth factor derived from lactose for Bifidobacterium, and Bifidobacterium breve 4006 on the fecal flora of normal subjects. All of the Bifidobacterium species tested, eight reference strains and B. breve 4006 were capable of fermenting TOS in vitro, while others, 2 Bacteroides strains and 4 Lactobacillus and Enterobacteriaceae strains, showed an appreciable growth among 55 cultures tested. It was evident that TOS is not intestinally absorbed by the recipient subjects, from hydrogen breath test. In vivo, TOS (3g or 10g/day) was observed to promote the growth of both administered B. breve 4006 and resident Bifidobacterium strains. Simultaneous administration of B. breve 4006 and TOS caused the suppression of gram negative anaerobes and aerobes, Bacteroidaceae and Enterobacteriaceae, and the reduction of fecal ammonia and urinary indican excretion. It is concluded that TOS is a typical bifidus factor.
- 著者
- Sae X. Morita Yanling Zhao Kohei Hasegawa Michael A. Fifer Mathew S. Maurer Muredach P. Reilly Hiroo Takayama Yuichi J. Shimada
- 出版者
- International Heart Journal Association
- 雑誌
- International Heart Journal (ISSN:13492365)
- 巻号頁・発行日
- vol.62, no.5, pp.1035-1041, 2021-09-29 (Released:2021-09-30)
- 参考文献数
- 32
- 被引用文献数
- 2
Septal reduction therapy (SRT) -i.e. septal myectomy and alcohol septal ablation-has been performed to treat medically refractory hypertrophic cardiomyopathy (HCM) for decades. However, it is largely unknown whether SRT prevents HCM-related cardiovascular events or death. The objective was to examine the effects of SRT on acute cardiovascular events and all-cause mortality in HCM. We performed a propensity score (PS) -matched study using databases that capture all hospitalizations and outpatient visits in New York state. We identified patients with HCM who underwent SRT between 2007 and 2014 (i.e. the SRT group) and those who had never had SRT but had at least one hospitalization for HCM during the same period (i.e. the control group). We performed PS matching at a 1:1 ratio. The primary outcome was a composite of acute cardiovascular events and all-cause mortality during 0-180 days and 181-360 days. The secondary outcome was 180- and 360-day all-cause mortality. We included 846 patients with HCM (423 PS-matched pairs). Patients who underwent SRT had a lower risk of the primary outcome event (0-180 days: odds ratio [OR], 0.54; 95% confidence intervals (CI), 0.37-0.80; P = 0.002 and 181-360 days: OR, 0.33; 95% CI, 0.22-0.51; P < 0.0001). Furthermore, the risk of all-cause mortality was lower at 180 days (OR, 0.37; 95% CI, 0.22-0.63; P = 0.0003) and 360 days post-SRT (OR, 0.32; 95% CI, 0.20-0.51; P < 0.0001). In conclusion, our PS-matched study using population-based datasets demonstrated that SRT was associated with a reduced risk of a composite of acute cardiovascular events and all-cause mortality in HCM during the first post-SRT year.